| | Intermittent | Mild Persistent | Moderate Persistent | Severe Persistent | | |
|--|-------------------------------|---|---|---------------------------------------|---|---|
| Daytime symptom frequency | $\leq 2 \text{ days/week}$ | 2–6 days/week | Daily | Several times/day | | |
| Nighttime awakenings | $\leq 2 \text{ nights/month}$ | 3–4 nights/month | >1 night/week | | Nightly | |
| SABA rescue | $\leq 2 \text{ days/week}$ | 2–6 days/week | Daily | ${\rm Several\ times/day}$ | | |
| Activity limitation | None | Minor | Some | | Extreme | |
| Exacerbations requiring systemic corticosteroids | 0-1/year | $\geq 2/\mathrm{year}$ | | | | |
| ${f Treatment}$ | SABA as needed | Low-dose inhaled corticosteroid or leukotriene receptor antagonist | Low-dose inhaled corticosteroid AND either LABA or leukotriene receptor antagonist | Medium-dose inhaled corticosteroid | Medium-dose inhaled corticosteroid AND either LABA or leukotriene receptor antagonist | High-dose inhaled corticosteroid AND either LABA or leukotriene receptor antagonist |
| Short-acting β_2 -agonists: albuterol, levalbuterol Inhaled corticosteroids: beclomethasone, budesonide, ciclesonide, fluticasone, mometasone Leukotriene receptor antagonists: montelukast, zafirlukast Long-acting β_2 -agonists: formoterol, salmeterol | | | | | | |
| Combined inhaled glucocorticoids and long-acting beta agonists: fluticasone-salmeterol, budesonide-formoterol | | | | | | |